Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1997-10-28
|
| pubmed:abstractText |
This study, we present evidence for a negatively acting control mechanism that coordinately suppresses the synthesis of the Th2 lymphokines IL-4, IL-5 and IL-6. This control mechanism operates in the murine thymoma cell line BW 5147. When cells of this line were fused to four independently established, well-defined Th2 cell clones, all resulting 74 lymphokine-secreting hybridomas secreted IL-2 which was not secreted by any of the parental Th2 cell clones. Most interestingly, however, none of the 74 hybridomas retained the capacity of the parental Th2 cells to express IL-4. Likewise, the secretion of IL-5 and IL-6 was also suppressed. Obviously, BW 5147 cells dominated the pattern of lymphokines produced, although the lymphokine pattern of Th2 cells was previously considered to be irreversibly fixed due to terminal differentiation of these cells. Suppression of IL-4 production was also observed at the mRNA level, as tested in Northern blot assays. Putative DNA target sequences for suppression of IL-4 gene transcription were not part of the proximal IL-4 promotor regions. Remote DNA control sequences may exist which coordinately regulate the proper, stage-specific expression of the Th2 lymphokines IL-4, IL-5 and IL-6.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-4,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-5,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Lymphokines,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0953-8178
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1347-53
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9310838-Animals,
pubmed-meshheading:9310838-Cell Fusion,
pubmed-meshheading:9310838-Clone Cells,
pubmed-meshheading:9310838-Hybridomas,
pubmed-meshheading:9310838-Immune Tolerance,
pubmed-meshheading:9310838-Interleukin-2,
pubmed-meshheading:9310838-Interleukin-4,
pubmed-meshheading:9310838-Interleukin-5,
pubmed-meshheading:9310838-Interleukin-6,
pubmed-meshheading:9310838-Lymphocyte Activation,
pubmed-meshheading:9310838-Lymphokines,
pubmed-meshheading:9310838-Mice,
pubmed-meshheading:9310838-Mice, Inbred AKR,
pubmed-meshheading:9310838-Mice, Inbred BALB C,
pubmed-meshheading:9310838-RNA, Messenger,
pubmed-meshheading:9310838-Rats,
pubmed-meshheading:9310838-Th2 Cells,
pubmed-meshheading:9310838-Thymoma,
pubmed-meshheading:9310838-Transcription, Genetic,
pubmed-meshheading:9310838-Tumor Cells, Cultured
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
A dominant mechanism coordinately suppresses the expression of Th2 lymphokines.
|
| pubmed:affiliation |
Institute of Clinical Microbiology, University of Erlangen/Nürnberg, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|